<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>LIDOCAINE HYDROCHLORIDE- lidocaine hydrochloride solution </strong><br>Rebel Distributors Corp<br></p></div>
<h1>LIDOCAINE HYDROCHLORIDE ORAL TOPICAL SOLUTION, USP (VISCOUS) 2%</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_66c79d1d-ea04-45c7-a696-27b8bab9f2c3"></a><a name="section-1"></a><p></p>
<p class="First">A Topical Anesthetic for the Mucous Membranes of the Mouth and Pharynx. </p>
<p><span class="Bold">For Oral Use Only.</span></p>
<p><span class="Bold">Rx Only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_8fb36041-db0e-4af5-b955-cba3b69049fd"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Lidocaine Hydrochloride Oral Topical Solution, USP (Viscous) 2% contains a local anesthetic agent and is administered topically. Lidocaine Hydrochloride Oral Topical Solution, USP (Viscous) 2% contains lidocaine hydrochloride, which is chemically designated as acetamide, 2-(diethylamino)-N- (2,6-dimethylphenyl)- , monohydrochloride and has the following structural formula:</p>
<p><img alt="Lidocaine Hydrochloride Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8a4c45c0-7eae-4296-ae2e-6d618228dc8b&amp;name=8a4c45c0-7eae-4296-ae2e-6d618228dc8b-01.jpg"></p>
<p>The molecular formula of lidocaine is C<span class="Sub">14</span>H<span class="Sub">22</span>N<span class="Sub">2</span>O. The molecular weight is 234.34.</p>
<p>Each mL contains 20 mg of lidocaine HCl. In addition each mL contains the following inactive ingredients: Carboxymethylcellulose sodium, methylparaben, natural orange flavor, propylparaben, purified water, saccharin sodium. The pH is adjusted to 5.0 to 7.0 by means of hydrochloric acid and/or sodium hydroxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_7c85c2f5-bd6e-4994-acaa-4f8d40e0d6dd"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_9547b328-c4bb-47ce-b632-ca83c281e9d3"></a><a name="section-3.1"></a><p></p>
<h2>Mechanism of Action:</h2>
<p class="First">Lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cd8b9d27-74e4-44e7-a538-0a24706c049c"></a><a name="section-3.2"></a><p></p>
<h2>Hemodynamics:</h2>
<p class="First">Excessive blood levels may cause changes in <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>, total peripheral resistance, and mean arterial pressure. These changes may be attributable to a direct depressant effect of the local anesthetic agent on various components of the cardiovascular system. The net effect is normally a modest <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> when the recommended dosages are not exceeded.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ac41793f-852a-4b57-b50d-30320be312f9"></a><a name="section-3.3"></a><p></p>
<h2>Pharmacokinetics and Metabolism:</h2>
<p class="First">Lidocaine is absorbed following topical administration to mucous membranes, its rate and extent of absorption being dependent upon concentration and total dose administered, the specific site of application, and duration of exposure. In general, the rate of absorption of local anesthetic agents following topical application occurs most rapidly after intratracheal administration. Lidocaine is also well-absorbed from the gastrointestinal tract, but little intact drug appears in the circulation because of biotransformation in the liver.</p>
<p>The plasma binding of lidocaine is dependent on drug concentration, and the fraction bound decreases with increasing concentration. At concentrations of 1 to 4 mcg of free base per mL, 60 to 80 percent of lidocaine is protein bound. Binding is also dependent on the plasma concentration of the alpha-1-acid glycoprotein.</p>
<p>Lidocaine crosses the blood-brain and placental barriers, presumably by passive diffusion.</p>
<p>Lidocaine is metabolized rapidly by the liver, and metabolites and unchanged drug are excreted by the kidneys. Biotransformation includes oxidative N-dealkylation, ring hydroxylation, cleavage of the amide linkage, and conjugation. N-dealkylation, a major pathway of biotransformation, yields the metabolites monoethylglycinexylidide and glycinexylidide. The pharmacological/toxicological actions of these metabolites are similar to, but less potent than, those of lidocaine. Approximately 90% of lidocaine administered is excreted in the form of various metabolites, and less than 10% is excreted unchanged. The primary metabolite in urine is a conjugate of 4-hydroxy-2, 6-dimethylaniline.</p>
<p>The elimination half-life of lidocaine following an intravenous bolus injection is typically 1.5 to 2.0 hours. Because of the rapid rate at which lidocaine is metabolized, any condition that affects liver function may alter lidocaine kinetics. The half-life may be prolonged two-fold or more in patients with liver dysfunction. Renal dysfunction does not affect lidocaine kinetics but may increase the accumulation of metabolites.</p>
<p>Factors such as <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span> and the use of CNS stimulants and depressants affect the CNS levels of lidocaine required to produce overt systemic effects. Objective adverse manifestations become increasingly apparent with increasing venous plasma levels above 6.0 mcg free base per mL. In the rhesus monkey arterial blood levels of 18-21 mcg/mL have been shown to be threshold for convulsive activity.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_91c03218-eef3-4a0e-95e2-3ff71961e65a"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Lidocaine Hydrochloride Oral Topical Solution, USP (Viscous) 2% is indicated for the production of topical anesthesia of irritated or inflamed mucous membranes of the mouth and pharynx. It is also useful for reducing <span class="product-label-link" type="condition" conceptid="4091505" conceptname="Gagging">gagging</span> during the taking of X-ray pictures and dental impressions.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_639e283f-5c5c-4466-be10-5c6540fd2aae"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Lidocaine is contraindicated in patients with a known history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to local anesthetics of the amide type, or to other components of the solution.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_bf6c3097-d735-4062-a660-e21afcdeea73"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">EXCESSIVE DOSAGE, OR SHORT INTERVALS BETWEEN DOSES, CAN RESULT IN HIGH PLASMA LEVELS AND SERIOUS ADVERSE EFFECTS. PATIENTS SHOULD BE INSTRUCTED TO STRICTLY ADHERE TO THE RECOMMENDED DOSAGE AND ADMINISTRATION GUIDELINES AS SET FORTH IN THIS PACKAGE INSERT.</p>
<p>THE MANAGEMENT OF SERIOUS ADVERSE REACTIONS MAY REQUIRE THE USE OF RESUSCITATIVE EQUIPMENT, OXYGEN, AND OTHER RESUSCITATIVE DRUGS.</p>
<p>Lidocaine Hydrochloride Oral Topical Solution, USP (Viscous) 2% should be used with extreme caution if the mucosa in the area of application has been traumatized, since under such conditions there is the potential for rapid systemic absorption.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_19836e92-2724-43a5-810d-10e842e96772"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_7b4b39a7-ad78-4cc0-9cad-ac160e04007a"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">The safety and effectiveness of lidocaine depend on proper dosage, correct technique, adequate precautions, and readiness for emergencies (See <a href="#i4i_warnings_id_bf6c3097-d735-4062-a660-e21afcdeea73">WARNINGS</a> and <a href="#i4i_adverse_effects_id_350967cc-b91c-4628-8e53-b14cc9c97ef9">ADVERSE REACTIONS</a>). The lowest dosage that results in effective anesthesia should be used to avoid high plasma levels and serious adverse effects. Repeated doses of lidocaine may cause significant increases in blood levels with each repeated dose because of slow accumulation of the drug and/or its metabolites. Tolerance varies with the status of the patient. Debilitated, elderly patients, acutely ill patients, and children should be given reduced doses commensurate with their age, weight and physical condition. Lidocaine should also be used with caution in patients with severe <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> or <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>.</p>
<p>Lidocaine Hydrochloride Oral Topical Solution, USP (Viscous) 2% should be used with caution in persons with known drug sensitivities. Patients allergic to para-aminobenzoic acid derivatives (procaine, tetracaine, benzocaine, etc.) have not shown cross sensitivity to lidocaine.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_706a9984-fd6e-4830-a25d-4e6f70f9772b"></a><a name="section-7.2"></a><p></p>
<h2>Information for patients</h2>
<p class="First">When topical anesthetics are used in the mouth or throat, the patient should be aware that the production of topical anesthesia may impair swallowing and thus enhance the danger of <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span>. For this reason, food should not be ingested for 60 minutes following use of local anesthetic preparations in the mouth or throat area. This is particularly important in children because of their frequency of eating.</p>
<p><span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">Numbness</span> of the tongue or buccal mucosa may increase the danger of biting <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>. For this reason food and/or chewing gum should not be used while the mouth or throat area is anesthetized.</p>
<p>PATIENTS SHOULD BE INSTRUCTED TO STRICTLY ADHERE TO DOSING INSTRUCTIONS, AND TO KEEP THE SUPPLY OF MEDICATION OUT OF THE REACH OF CHILDREN.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_87f4d4ee-ecc7-41bc-a71a-5ed7ca0bad40"></a><a name="section-7.3"></a><p></p>
<h2>Carcinogenesis, mutagenesis, impairment of fertility</h2>
<p class="First">Studies of lidocaine in animals to evaluate the carcinogenic and mutagenic potential or the effect on fertility have not been conducted.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_7c7014ed-5544-4d42-8313-a582caf067ac"></a><a name="section-7.4"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_c011906c-1cfc-4b8f-8f25-feece5264701"></a><a name="section-7.4.1"></a><p></p>
<h3>Teratogenic effects</h3>
<p class="First">Pregnancy Category B. Reproduction studies have been performed in rats at doses up to 6.6 times the human dose and have revealed no evidence of harm to the fetus caused by lidocaine. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used in pregnancy only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_e124b746-4703-4a13-bf53-d96935f81f85"></a><a name="section-7.5"></a><p></p>
<h2>Nursing mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when lidocaine is administered to nursing women.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_edbdc938-ba86-45b1-a705-52d44c81d631"></a><a name="section-7.6"></a><p></p>
<h2>Pediatric use</h2>
<p class="First">Dosages in children should be reduced, commensurate with age, body weight and physical condition. (See <a href="#i4i_dosage_admin_id_4c29125d-97df-460d-b21a-950bf8ec39fc">DOSAGE AND ADMINISTRATION</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_350967cc-b91c-4628-8e53-b14cc9c97ef9"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Adverse experiences following the administration of lidocaine are similar in nature to those observed with other amide local anesthetic agents. These adverse experiences are, in general, dose-related and may result from high plasma levels caused by excessive dosage or rapid absorption, or may result from a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, idiosyncrasy, or diminished tolerance on the part of the patient. Serious adverse experiences are generally systemic in nature. The following types are those most commonly reported:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_269d37a1-002f-4709-a7b5-88cb2bab5e6e"></a><a name="section-8.1"></a><p></p>
<h2>Central Nervous System:</h2>
<p class="First">CNS manifestations are excitatory and/or depressant and may be characterized by <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">apprehension</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, blurred or <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">double vision</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, sensations of heat, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> or <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconsciousness</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and arrest. The excitatory manifestations may be very brief or may not occur at all, in which case the first manifestation of toxicity may be <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> merging into <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconsciousness</span> and <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span> following the administration of lidocaine is usually an early sign of a high blood level of the drug and may occur as a consequence of rapid absorption.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_55a04b61-204b-46f2-9fb7-ffa2df7019b5"></a><a name="section-8.2"></a><p></p>
<h2>Cardiovascular System:</h2>
<p class="First">Cardiovascular manifestations are usually depressant and are characterized by <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span>, which may lead to <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5a0472de-e90e-431d-b43e-41a3637f87bf"></a><a name="section-8.3"></a><p></p>
<h2>Allergic:</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> are characterized by cutaneous lesions, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> or <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> may occur as a result of sensitivity either to the local anesthetic agent or to the methylparaben and/or propylparaben used in this formulation. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> as a result of sensitivity to lidocaine are extremely rare and, if they occur, should be managed by conventional means. The detection of sensitivity by skin testing is of doubtful value.</p>
<p>To report SUSPECTED ADVERSE REACTIONS, contact Hi-Tech Pharmacal Co., Inc. at 1-800-262-9010 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_085e48e6-8986-4995-9b9b-ce5a49a2f875"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE:</h1>
<p class="First">Acute emergencies from local anesthetics are generally related to high plasma levels encountered during therapeutic use of local anesthetics. (See <a href="#i4i_adverse_effects_id_350967cc-b91c-4628-8e53-b14cc9c97ef9">ADVERSE REACTIONS</a>, <a href="#i4i_warnings_id_bf6c3097-d735-4062-a660-e21afcdeea73">WARNINGS</a>, and <a href="#i4i_precautions_id_19836e92-2724-43a5-810d-10e842e96772">PRECAUTIONS</a>).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b1e13884-4f0c-4c3d-97ee-3eece9c2c7d6"></a><a name="section-9.1"></a><p></p>
<h2>Management of Local Anesthetic Emergencies:</h2>
<p class="First">The first consideration is prevention, best accomplished by careful and constant monitoring of cardiovascular and respiratory vital signs and the patient's state of consciousness after each local anesthetic administration.</p>
<p>The first step in the management of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> consists of immediate attention to the maintenance of a patent airway and assisted or controlled ventilation with oxygen. In situations where trained personnel are readily available, ventilation should be maintained and oxygen should be delivered by a delivery system capable of permitting immediate positive airway pressure by mask. Immediately after the institution of these ventilatory measures, the adequacy of the circulation should be evaluated, keeping in mind that drugs used to treat <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> sometimes depress the circulation when administered intravenously. Should <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> persist despite adequate respiratory support, and if the status of the circulation permits, small increments of an ultra-short acting barbiturate (such as thiopental or thiamylal) or a benzodiazepine (such as diazepam) may be administered intravenously. The clinician should be familiar, prior to use of local anesthetics, with these anticonvulsant drugs. Supportive treatment of circulatory <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> may require administration of intravenous fluids and, when appropriate, a vasopressor as indicated by the clinical situation (e.g., ephedrine).</p>
<p>If not treated immediately, both <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> and cardiovascular <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> can result in <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>. If <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> should occur, standard cardiopulmonary resuscitative measures should be instituted.</p>
<p>Dialysis is of negligible value in the treatment of acute overdosage with lidocaine.</p>
<p>The oral LD<span class="Sub">50</span> of lidocaine in non-fasted female rats is 459 (346-773) mg/kg (as the salt) and 214 (159-324) mg/kg (as the salt) in fasted female rats.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_4c29125d-97df-460d-b21a-950bf8ec39fc"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f5a7ad5f-38dc-44e6-aba8-8648f3afe49e"></a><a name="section-10.1"></a><p></p>
<h2>Adult:</h2>
<p class="First">The maximum recommended single dose of Lidocaine Hydrochloride Oral Topical Solution, USP (Viscous) 2% for healthy adults should be such that the dose of lidocaine HCI does not exceed 4.5 mg/kg or 2 mg/lb body weight and does not in any case exceed a total of 300 mg.</p>
<p>For symptomatic treatment of irritated or inflamed mucous membranes of the mouth and pharynx, the usual adult dose is one 15 mL tablespoonful undiluted. For use in the mouth, the solution should be swished around in the mouth and spit out. For use in the pharynx, the undiluted solution should be gargled and may be swallowed. This dose should not be administered at intervals of less than three hours, and not more than eight doses should be given in a 24-hour period.</p>
<p>The dosage should be adjusted commensurate with the patient's age, weight and physical condition. (See <a href="#i4i_precautions_id_19836e92-2724-43a5-810d-10e842e96772">PRECAUTIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7477f787-6f9e-4ac5-aba3-d2c5b4914964"></a><a name="section-10.2"></a><p></p>
<h2>Pediatric:</h2>
<p class="First">Care must be taken to ensure correct dosage in all pediatric patients as there have been cases of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> due to inappropriate dosing.</p>
<p>It is difficult to recommend a maximum dose of any drug for children since this varies as a function of age and weight. For children over 3 years of age who have a normal lean body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> and normal body development, the maximum dose is determined by the child's weight or age. For example: in a child of 5 years weighing 50 lbs., the dose of lidocaine hydrochloride should not exceed 75-100 mg (3/4 to 1 teaspoonful).</p>
<p>For infants and in children under 3 years of age, 1/4 teaspoonful of the solution should be accurately measured and applied to the immediate area with a cotton-tipped applicator. This dose should not be administered at intervals of less than three hours. Not more than four doses should be given in a 12-hour period.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_df5bbdb6-74e9-40b7-b579-addbad5fdf51"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Lidocaine Hydrochloride Oral Topical Solution, USP (Viscous) 2% is a clear, viscous liquid with a very slight orange flavor available in 100 mL polyethylene squeeze bottles.</p>
<p>The solution should be stored at controlled room temperature 15°- 30°C (59°- 86°F).</p>
<p><span class="Bold">SHAKE WELL BEFORE USE.</span></p>
<p><br></p>
<p><br></p>
<p>Manufactured by: Hi-Tech Pharmacal Co., Inc.</p>
<p>Amityville, NY 11701</p>
<p>Made in U.S.A.</p>
<p>Repackaged by:</p>
<p>Rebel Distributors Corp</p>
<p>Thousand Oaks, CA 91320</p>
<p><br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_01bfe6c5-edbc-4863-b7b0-ea24eef69a09"></a><a name="section-12"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure">
<img alt="Lidocaine HCl 2%" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8a4c45c0-7eae-4296-ae2e-6d618228dc8b&amp;name=8a4c45c0-7eae-4296-ae2e-6d618228dc8b-02.jpg"><p class="MultiMediaCaption"></p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LIDOCAINE HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">lidocaine hydrochloride solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:21695-783(NDC:50383-775)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL, TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LIDOCAINE HYDROCHLORIDE</strong> (LIDOCAINE) </td>
<td class="formItem">LIDOCAINE HYDROCHLORIDE</td>
<td class="formItem">20 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CARBOXYMETHYLCELLULOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ORANGE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SACCHARIN SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:21695-783-00</td>
<td class="formItem">100 mL in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040014</td>
<td class="formItem">07/10/1995</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Rebel Distributors Corp
							(118802834)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Rebel Distributors Corp</td>
<td class="formItem"></td>
<td class="formItem">118802834</td>
<td class="formItem">RELABEL, REPACK</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>8a4c45c0-7eae-4296-ae2e-6d618228dc8b</div>
<div>Set id: 8a4c45c0-7eae-4296-ae2e-6d618228dc8b</div>
<div>Version: 1</div>
<div>Effective Time: 20101001</div>
</div>
</div> <div class="DistributorName">Rebel Distributors Corp</div></p>
</body></html>
